Staff View: Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease

The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chan, Wah-Kheong, Tan, Soek-Siam, Chan, Siew-Pheng, Lee, Yeong-Yeh, Tee, Hoi-Poh, Mahadeva, Sanjiv, Goh, Khean-Lee, Ramli, Anis Safura, Mustapha, Feisul, Kosai, Nik Ritza, Raja Ali, Raja Affendi
Format:	Article
Published:	Blackwell Publishing 2022
Subjects:	R Medicine RC Internal medicine
Online Access:	http://eprints.um.edu.my/43038/
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my.um.eprints.43038
record_format	eprints
spelling	my.um.eprints.430382023-09-19T03:37:31Z http://eprints.um.edu.my/43038/ Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease Chan, Wah-Kheong Tan, Soek-Siam Chan, Siew-Pheng Lee, Yeong-Yeh Tee, Hoi-Poh Mahadeva, Sanjiv Goh, Khean-Lee Ramli, Anis Safura Mustapha, Feisul Kosai, Nik Ritza Raja Ali, Raja Affendi R Medicine RC Internal medicine The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, and public health. A modified Delphi process was used to prepare the consensus statements. The panel recognized the high and increasing prevalence of the disease and the consequent anticipated increase in liver-related complications and mortality. Cardiovascular disease is the leading cause of mortality in MAFLD patients; therefore, cardiovascular disease risk assessment and management is important. A simple and clear liver assessment and referral pathway was agreed upon, so that patients with more severe MAFLD can be linked to gastroenterology/hepatology care, while patients with less severe MAFLD can remain in primary care or endocrinology, where they are best managed. Lifestyle intervention is the cornerstone in the management of MAFLD. The panel provided a consensus on the use of statin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 agonist, pioglitazone, vitamin E, and metformin, as well as recommendations on bariatric surgery, screening for gastroesophageal varices and hepatocellular carcinoma, and liver transplantation in MAFLD patients. Increasing the awareness and knowledge of the various stakeholders on MAFLD and incorporating MAFLD into existing noncommunicable disease-related programs and activities are important steps to tackle the disease. These consensus statements will serve as a guide on MAFLD for clinicians and other stakeholders. Blackwell Publishing 2022-05 Article PeerReviewed Chan, Wah-Kheong and Tan, Soek-Siam and Chan, Siew-Pheng and Lee, Yeong-Yeh and Tee, Hoi-Poh and Mahadeva, Sanjiv and Goh, Khean-Lee and Ramli, Anis Safura and Mustapha, Feisul and Kosai, Nik Ritza and Raja Ali, Raja Affendi (2022) Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. Journal of Gastroenterology and Hepatology, 37 (5). pp. 795-811. ISSN 0815-9319, DOI https://doi.org/10.1111/jgh.15787 <https://doi.org/10.1111/jgh.15787>. 10.1111/jgh.15787
institution	Universiti Malaya
building	UM Library
collection	Institutional Repository
continent	Asia
country	Malaysia
content_provider	Universiti Malaya
content_source	UM Research Repository
url_provider	http://eprints.um.edu.my/
topic	R Medicine RC Internal medicine
spellingShingle	R Medicine RC Internal medicine Chan, Wah-Kheong Tan, Soek-Siam Chan, Siew-Pheng Lee, Yeong-Yeh Tee, Hoi-Poh Mahadeva, Sanjiv Goh, Khean-Lee Ramli, Anis Safura Mustapha, Feisul Kosai, Nik Ritza Raja Ali, Raja Affendi Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
description	The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD). The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine, and public health. A modified Delphi process was used to prepare the consensus statements. The panel recognized the high and increasing prevalence of the disease and the consequent anticipated increase in liver-related complications and mortality. Cardiovascular disease is the leading cause of mortality in MAFLD patients; therefore, cardiovascular disease risk assessment and management is important. A simple and clear liver assessment and referral pathway was agreed upon, so that patients with more severe MAFLD can be linked to gastroenterology/hepatology care, while patients with less severe MAFLD can remain in primary care or endocrinology, where they are best managed. Lifestyle intervention is the cornerstone in the management of MAFLD. The panel provided a consensus on the use of statin, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 agonist, pioglitazone, vitamin E, and metformin, as well as recommendations on bariatric surgery, screening for gastroesophageal varices and hepatocellular carcinoma, and liver transplantation in MAFLD patients. Increasing the awareness and knowledge of the various stakeholders on MAFLD and incorporating MAFLD into existing noncommunicable disease-related programs and activities are important steps to tackle the disease. These consensus statements will serve as a guide on MAFLD for clinicians and other stakeholders.
format	Article
author	Chan, Wah-Kheong Tan, Soek-Siam Chan, Siew-Pheng Lee, Yeong-Yeh Tee, Hoi-Poh Mahadeva, Sanjiv Goh, Khean-Lee Ramli, Anis Safura Mustapha, Feisul Kosai, Nik Ritza Raja Ali, Raja Affendi
author_facet	Chan, Wah-Kheong Tan, Soek-Siam Chan, Siew-Pheng Lee, Yeong-Yeh Tee, Hoi-Poh Mahadeva, Sanjiv Goh, Khean-Lee Ramli, Anis Safura Mustapha, Feisul Kosai, Nik Ritza Raja Ali, Raja Affendi
author_sort	Chan, Wah-Kheong
title	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
title_short	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
title_full	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
title_fullStr	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
title_full_unstemmed	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
title_sort	malaysian society of gastroenterology and hepatology consensus statement on metabolic dysfunction-associated fatty liver disease
publisher	Blackwell Publishing
publishDate	2022
url	http://eprints.um.edu.my/43038/
_version_	1778161688240979968
score	13.211869

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease

Similar Items